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Nitric oxide (NO) is a molecule of
surprises: a gas that is a biological
signaling molecule; a radical that is an
essential regulator of numerous cell
types; and a pollutant that has been
the subject of over 30,000 papers in
biology and medicine. How can a
start-up company possibly tackle
such an unwieldy subject area?
The contradictions of NicOx S.A.
(Sophia-Antipolis, France) match
those of its subject matter. A French
company, NicOx is headed by two
Italians and an American. With just
20 employees it is already overseeing
10 clinical trials (ongoing or
imminent) and coordinating over 50
research collaborations. And its
primary promise is that it will beat
out a class of drugs — the
cyclooxygenase 2 (Cox2)-specific
non-steroidal anti-inflammatory
drugs (NSAIDs) — that were
greeted with the biggest fanfare that
the pharmaceutical industry has seen
for the last 20 years. The history of
NO is not exactly lacking in
dramatics, but if NicOx has their way
the climax will be the triumph of NO
as a therapeutic for everything from
pain and inflammation to
cardiovascular disease, Alzheimer’s
disease and osteoporosis. 
From Alfred to That Prize
The bizarre story of NO research
starts in the 1890s with Alfred Nobel.
Nobel made a large part of his
fortune by realizing that he could
pack the highly unstable explosive
nitroglycerin into a silica base to
produce dynamite. But on his death
bed he was confronted with
nitroglycerin in another form. As he
wrote to a friend: “Isn’t it the irony
of fate that I have been prescribed
nitroglycerin, to be taken internally!
They call it Trinitrin, so as not to
scare the chemist and the public.”
Nobel was suffering from angina
pectoris — chest pain caused by
insufficient blood supply to the heart
— and nitroglycerin was then, and
remains today, an effective
treatment. It works by dilating the
heart’s vessels to allow greater blood
flow. Nobel was not convinced and
declined his doctor’s offer.
Angina was far from the mind of
Ferid Murad (University of Virginia,
Charlottesville) in 1977. He was
simply looking for chemicals that
would shut off various interfering
enzymes so that he could study his
favorite — guanylyl cyclase (GC).
But by chance one of the chemicals
turned on GC, and suddenly Murad
had the first known activator of this
mysterious enzyme. Other activators
followed, including nitroglycerin.
A toxic gas may improve the most
widely used of all drugs. 
All the activators shared the
property that they could generate
NO and relax smooth muscle. In
1979, Louis Ignarro at Tulane
University, New Orleans, found that
bubbling NO near an isolated artery
triggered a relaxation response. “I
asked Murad: ‘Why do our bodies
have the machinery to respond to
nitroglycerin?’,” says Ignarro. “The
obvious conclusion was that our
bodies have an endogenous
nitrogenous compound of some
kind.” But evidence for the
endogenous compound was lacking
and NO itself was not a good
candidate. “Edwin Krebs said to me:
‘It’s a pollutant; it’s a chemical in the
air — why are you working on
this?’,” says Ignarro.
More puzzling information came
from Robert Furchgott of the State
University of New York (SUNY) in
Brooklyn. He had been struggling
with the finding that acetylcholine, a
known relaxant in the body, caused
isolated blood vessels to contract. He
returned to this quandary by mistake
in 1978, when a technician left out a
planned washing step in an unrelated
experiment. For the first time the
technician observed relaxation after
in vitro application of acetylcholine.
The difference between the
earlier and later experiments was in
the method of preparing the blood
vessels. In the earlier experiments
Furchgott had made strips. But in
carefully drawing the cut strips over
his finger he had wiped off a critical
layer of endothelial cells. The rings
of vessels used in the later
experiments retained the endothelial
cells, so they could respond to
acetylcholine to produce what
Furchgott now dubbed endothelium-
derived relaxing factor (EDRF).
From Furchgott’s paper in 1980 it
took six years to deduce that EDRF
was NO. “Reading over these papers
now it is amazing that we didn’t draw
these conclusions five years before,”
says Ignarro. But, he says, “very few
people went out on a limb to suggest
what EDRF might be.” NO was
implicated by evidence from
researchers including Murad and
Ignarro, but many feel that the
knockout punch came from Salvador
Moncada (then at the Wellcome
Research Laboratories in Beckenham,
England), who demonstrated in a
1987 Nature paper that the amount of
NO produced by a known relaxant
was sufficient to cause a full relaxant
response. Unfortunately the Nobel
Prize can be awarded to at most three
people, so in a controversial decision
the 1998 Nobel for Physiology or
Medicine was presented to Murad,
Ignarro and Furchgott. 
NO does it all
As NO research boomed, scientists
realized that NO not only relaxed
blood vessels, but also acted as a
messenger in the immune and
nervous systems. This increased the
number of possible applications of
NO-related drugs, but also made it
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more likely that there would be
problems with side-effects. A number
of inhibitors of NO synthases (NOS)
fell into this trap: although they
inhibited the immune system’s
inducible NOS (iNOS), they also
jammed up the endothelial NOS
(eNOS) and caused an increase in
blood pressure (hypertension). 
John Wallace (University of
Calgary, Alberta, Canada) and
Giuseppe Cirino (University of
Naples, Italy) were interested in more
subtle modifications of NO levels. It
was well known that the beneficial
effects of NSAIDs (including the
painkillers ibuprofen, naproxen and
aspirin) were compromised by their
toxicity in the gastrointestinal (GI)
system. “We identified that two of the
key problems with NSAID GI
toxicity were reduced blood flow and
increased neutrophil adhesion,” says
Wallace. “Those were both things
that we knew could be counteracted
by NO.”
This idea was the basis for
NicOx. The NO is supplied by a
nitroxybutylester moiety on the
NSAID, which was designed and
synthesized by Piero Del Soldato,
now the executive vice president of
research at NicOx. Cellular esterases
release the parent NSAID, and
cytochrome oxidases transform the
nitrate moiety into NO.
Initial tests in animals and then
humans brought a pleasant surprise.
“We were very impressed that there
was no modification in blood
pressure,” says Del Soldato. “This
was unexpected.” The key, he says,
is the slow release of NO. “You are
producing the NO at a level that is
unable to overcome the homeostatic
process. You release NO but in a
controlled way.”
The beneficial effects of the NO
moiety extend beyond the
prevention of GI ulceration and
bleeding. Inflammation, says Del
Soldato, “is already activated when
you give the compound, so inhibiting
one receptor is not enough.” Luckily
NO affects up to 7 or 8 different cell
types involved in inflammation.
A virtual company
The NO-NSAIDs’ main competition
is the Cox2 inhibitors, which hit the
inflammation-induced Cox2 enzyme,
but spare its constitutive relative,
Cox1. The selectivity is important
because Cox1 helps to protect the
stomach lining.
The Cox2 compounds nearly
killed the NO-NSAID project before
it started. Armed with an idea and a
compound, Wallace says he and his
colleagues “shopped it around to big
pharma, [but] at the time these
companies were developing Cox2
inhibitors so we didn’t get much
interest. We realized we would be
better off developing it ourselves.”
That was easier said than done.
“For three years we lived on our own
financial resources,” says NicOx
CEO Michele Garufi. “In Italy in
1994 it was impossible to find
venture capital,” and British venture
capital “didn’t invest beyond the
Channel.” Finally the money arrived
but with one condition: that the
company move to France. 
Not that the team was forgotten
in Italy. “We are very famous in Italy
only because we are the first two
crazy guys to do something that is
quite normal in the US,” says Garufi.
“We were non-conventional Italians
— we wanted to take risks.”
The funding was still modest, so to
make it last longer the company
contracted most of its work out to
university researchers. “We were a
little forced to do that because we
didn’t have the funds to do otherwise,”
says Garufi. “But sometimes you are
forced into a model and then you
realize it’s the right model.” NicOx has
stayed with contract research and even
now has only 20 full-time employees.
Working in a field as vast as NO
biology, Garufi says that “it would
have been too pretentious and too
limited to group within our company
only a few good scientists. It’s much
more productive to have all the top
professors working for us in their
own laboratories or institutes.”
“That gives you flexibility in
closing your projects by finishing the
research contract rather than having
to fire five people,” he says. “And it
gives a lot of credibility to our
research. The data are coming from
top level professors who have
credibility and a reputation.”
The main focus in-house is the
chemical laboratories, which help the
company keep the most important
preclinical information proprietary.
But if the company ever wants some
biological work done “we always find
more people than we need,” says
Garufi, “because NO is a hot field.”
The number of collaborations has
allowed the company to branch out.
By adding NO-generating moieties to
a variety of common drugs, the
company is moving into areas such as
urinary incontinence (both NO and
NSAIDs have an effect), osteoporosis
(NO inhibits bone-eating osteoclasts),
asthma (NO and a steroid relax
bronchial smooth muscles),
thrombosis (NO augments the anti-
clotting effects of aspirin), high blood
pressure (NO may improve standard
drugs such as beta blockers) and even
Alzheimer’s disease (with NO acting
as an anti-inflammatory).
Even in pain and inflammation,
Del Soldato feels NicOx has the
upper hand. “In terms of safety we
have an advantage because Cox2-
specific inhibitors are good [only]
when the tissue is not [already]
compromised,” he says. And, he says,
“Cox1 is critical. It has a relevant role
in inflammation and thrombosis.” A
recent study, for example, indicates
that the heart-protecting effect of
naproxen is lost when Merck’s Cox2
inhibitor Vioxx is used instead. 
“I saw the flaws in the Cox2
approach early on,” says Wallace.
“The marketing was getting way
ahead of the science. We are being
vindicated now.” Garufi’s assessment
of the situation is more understated,
perhaps more European. When
NicOx began, he says, “there were
many risks. But so far so good.”
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